IPAMORELIN:
THE SELECTIVE GHS LITERATURE.

Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) — a G-protein-coupled receptor (GPCR) expressed on anterior pituitary somatotrophs, hypothalamic neurons, and enteric nervous system cells — with a Ki of approximately 1.0–1.5 nM. That affinity is three-to-five-fold lower than GHRP-2 (~0.3–0.4 nM Ki), but the selectivity profile diverges sharply.

Binding to pituitary somatotroph GHS-R1a activates Gq/11-protein signaling, triggering phospholipase C, IP3-mediated release of intracellular Ca2+, and a discrete pulse of GH secretion. The downstream GH pulse stimulates hepatic and peripheral IGF-1 production via GH receptor → JAK2/STAT5 signaling. IGF-1, in turn, engages the mTOR and PI3K/Akt pathways that mediate anabolic effects on protein synthesis and bone formation.

The defining pharmacological property of ipamorelin is its failure to engage the corticotroph (ACTH/cortisol) and lactotroph (prolactin) axes. In anesthetized rats and conscious swine, ipamorelin did not elevate ACTH or cortisol at doses exceeding 200-fold its GH-releasing ED50, and did not activate prolactin or TSH secretion.^[1] A 2020 review designated ipamorelin the "prototypical selective GHS" — the compound that established the mechanistic foundation for the GHS drug development programs that followed.^[17]

Ipamorelin also activates GHS-R1a expressed in the hypothalamus and enteric nervous system, explaining appetite and GI motility effects that are documented in the research record and that appear to be at least partially GH-independent.^[6]

Three primary rodent studies assessed ipamorelin's effects on bone formation and body composition.

Johansen et al. (1999) administered ipamorelin subcutaneously in three divided doses totaling 18, 90, or 450 mcg/day to adult female Sprague-Dawley rats for 15 days. Longitudinal bone growth rate increased in a dose-dependent manner from 42 mcm/day (control) to 44, 50, and 52 mcm/day in the three treatment groups.^[2] Total circulating IGF-1 levels were unchanged, suggesting that the bone growth effect was mediated by a local GH-dependent mechanism rather than by changes in systemic IGF-1.^[2]

Svensson et al. (2000) delivered ipamorelin continuously via osmotic minipump at 0.5 mg/kg/day for 12 weeks in young adult female Sprague-Dawley rats. Total tibial and vertebral bone mineral content (BMC) increased significantly.^[4] In vitro pQCT analysis showed that cortical bone enlargement was driven by increased cross-sectional area via periosteal expansion — periosteal bone apposition — rather than by increased volumetric bone mineral density.^[4]

Andersen et al. (2001) studied ipamorelin's capacity to counteract glucocorticoid-induced bone loss. Adult female Wistar rats (8 months) received prednisolone simultaneously with ipamorelin at 100 mcg/kg three times daily subcutaneously for three months. The periosteal bone formation rate increased four-fold in animals receiving both glucocorticoid and ipamorelin compared with glucocorticoid alone.^[3] Muscle maximum tetanic tension was also significantly improved in the combined treatment group.^[3]

A 21-day chronic treatment protocol in young female Wistar rats additionally demonstrated that repeated ipamorelin administration produced selective somatotroph sensitization: only ipamorelin-pretreated animals showed elevated intracellular GH content following subsequent in vitro stimulation, with increased somatotroph secretory granule volume density.^[5]

Ipamorelin's GHS-R1a activity in the enteric nervous system was examined in two rodent pharmacology studies and one Phase 2 human clinical trial.

Venkova et al. (2009) established preclinical activity: a single IV dose of 1 mg/kg reduced time to first bowel movement in a rat postoperative ileus model; repetitive dosing at 0.1 or 1 mg/kg four times daily over two days significantly increased cumulative fecal pellet output, food intake, and body weight gain compared with vehicle control.^[8]

Greenwood-Van Meerveld et al. (2012) characterized the mechanism: IV ipamorelin at 0.014 mcmol/kg reduced gastric radioactivity retention in a surgical postoperative ileus rat model from 78% (post-surgery vehicle) to approximately 52%, approaching non-operated control levels of 44%.^[9] In vitro analysis of isolated gastric tissue showed that ipamorelin normalized contractile response to acetylcholine via activation of cholinergic enteric neurons.^[9]

Beck et al. (2014) conducted the only Phase 2 human clinical trial involving ipamorelin to date: a prospective, randomized, double-blind, placebo-controlled study (NCT00672074) enrolling 114 adults undergoing small and large bowel resection.^[10] Ipamorelin was administered intravenously at 0.03 mg/kg twice daily for up to seven post-operative days. The compound was well tolerated: adverse event rates were 87.5% in the ipamorelin arm versus 94.8% in the placebo arm. The primary efficacy endpoint showed a 7.3-hour numeric improvement over placebo (25.3 h vs 32.6 h) that did not reach statistical significance (p=0.15).^[10]

Aagaard et al. (2009) examined ipamorelin's effect on steroid-induced nitrogen wasting in prednisolone-treated Sprague-Dawley rats.^[7] Ipamorelin at 0.5 mg/kg/day reduced hepatic urea-nitrogen synthesis capacity by 20% (p<0.05), decreased urea cycle enzyme expression, neutralized nitrogen balance, and normalized organ nitrogen contents — counteracting the nitrogen-wasting effects of glucocorticoid treatment.^[7]

Lall et al. (2001) documented GH-independent adiposity effects in both GH-deficient (lit/lit) and GH-intact mice receiving ipamorelin or GHRP-6 intraperitoneally.^[6] Both compounds elevated fat pad weights relative to body weight and increased serum leptin and food intake via hypothalamic GHS-R1a activation — effects that occurred independently of changes in circulating GH.^[6] This finding is mechanistically relevant: chronic GHS-R1a agonism may have appetite and fat deposition effects that are not mediated by GH itself, and the directionality (increased adiposity) is opposite to GH's established lipolytic effect.

A 2024 Physiology & Behavior study compared ipamorelin and anamorelin in a ferret cisplatin-induced weight loss and emesis model.^[15] Intraperitoneal ipamorelin inhibited cisplatin-induced weight loss by approximately 24% during the delayed phase (48–72 h post-cisplatin). Unlike anamorelin given intracerebroventricularly, ipamorelin did not demonstrate significant anti-emetic properties, indicating that ipamorelin's weight-preservation activity in this model operated through peripheral rather than central mechanisms.^[15]

A 2025 review of GHS history and clinical development placed ipamorelin within the class context: the compound's selectivity profile — GH release without ACTH/cortisol/prolactin co-stimulation — is cited as the mechanistic precedent that informed subsequent GHS programs (capromorelin, anamorelin) advanced to clinical approval or near-approval for cachexia indications.^[17] Ipamorelin itself has no approved cachexia indication and no ongoing Phase 3 program as of 2025.

Ankersen et al. (1998) published structure-activity work derived from the ipamorelin scaffold, producing peptidomimetic analogs including NNC 26-0235 and NNC 26-0323.^[13] NNC 26-0235, a tetrapeptide, achieved approximately 10% oral bioavailability in dogs at 1.8 mg/kg — a greater than 10-fold increase in basal GH — demonstrating that the ipamorelin scaffold could support orally bioavailable GHS design.^[13]

By comparison, intranasal bioavailability of ipamorelin itself is approximately 20% in rats, lower than related structural analogs NNC 26-0194 and NNC 26-0235 (~50%).^[11] The scaffold's tractability for next-generation oral GHS development was established by this series but ipamorelin itself has not progressed toward an orally administered form.